OnCore Login

Return to Trial Database

HCRN-LUN93-2

A Phase III Trial of Maintenance Daily Oral VP-16 vs no Further Therapy Following Induction Chemotherapy with VP-16 plus Ifosfamide plus Cisplatin (VIP) in Extensive Small Cell Lung Cancer

Status

Study Completed

Cancer Type(s)

Lung

Study Contact

Publications

Maintenance Daily Oral Etoposide Versus No Further Therapy Following Induction Chemotherapy With Etoposide Plus Ifosfamide Plus Cisplatin In Extensive Small Cell Lung Cancer
  • NH Hanna, AB Sandler, PJ Loehrer Sr., R Ansari, SH Jung, K Lane, LH Einhorn
Phase III Trial of Maintenance Daily Oral VP-16 Versus No Further Therapy Following Induction Chemotherapy With VP-16 (V) Plus Ifosfamide (I) Plus Cisplatin (P) (VIP) In Extensive Small Cell Lung Cancer (SCLC)
  • A Sandler, R Ansari, S Saxman, P Walker, MJ Wasielewski, F Monaco, J Hayes, LH Einhorn
A Phase III Study of VP16 plus Cisplatin (VP) alone or with Ifosfamide (VIP) in Previously Untreated Patients (PTS) with Extensive Small Cell Carcinoma of the LUNG (SCLC)
  • A Sandler, PJ Loehrer, R Ansari, R Gonin, MJ Wasielewski, LH Einhorn
A Phase III Study of VP16 plus Cisplatin (VP) alone or with Ifosfamide (VIP) in Previously Untreated Patients with Extensive Small Cell Carcinoma of the Lung (SCLC)
  • R Ansari, PJ Loehrer, R Gonin, MJ Wasielewski, LH Einhorn
Maintenance Daily Oral Etoposide versus No Further Therapy Following Induction Chemotherapy with Etoposide plus Ifosfamide plus Cisplatin in Extensive Small-Cell Lung Cancer: A Randomized Trial
  • NH Hanna, AB Sandler, PJ Loehrer Sr., R Ansari, SH Jung, K Lane, LH Einhorn
Cisplatin Plus Etoposide With and Without Ifosfamide in Extensive Small-Cell Lung Cancer
  • PJ Loehrer, R Ansari, R Gonin, F Monaco, W Fisher, A Sandler, LH Einhorn

Trial Locations

All sites in which the trial HCRN-LUN93-2 being conducted in.
No data was found
  • 7676 Interactive Way, Suite 120, Indianapolis, IN 46278